The investigational drug camicinal for the treatment of gastroparesis

Bibliography

• Choung RS, Locke GR, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012;107(1):82-8
   PubMed Web of Science ®Google Scholar
• Jung H-K, Choung RS, Locke GR, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009;136(4):1225-33
   PubMed Web of Science ®Google Scholar
• Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat Rev Gastroenterol Hepatol 2011;8:438-53
   PubMed Web of Science ®Google Scholar
• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108(1):18-37. quiz 38
   PubMed Web of Science ®Google Scholar
• Hasler WL. Emerging drugs for the treatment of gastroparesis. Expert Opin Emerg Drugs 2014;19(2):261-79
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Nguyen LAB, Snape WJ, et al. Changes in Quality of Life and Symptoms in a Large Cohort of Patients With Gastroparesis Followed Prospectively for 48 Weeks. Gastroenterology 2010;138(5):S-155
   Google Scholar
• Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011;9(12):1056-64. quiz e133-4
   PubMed Web of Science ®Google Scholar
• Linnik MD, Butler BT, Gaddis RR, Ahmed NK. Analysis of serotonergic mechanisms underlying benzamide-induced gastroprokinesis. J Pharmacol Exp Ther 1991;259(2):501-7
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3(3):138-48
   PubMedGoogle Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31(1):11-19
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Press announcements - FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. Office of the Commissioner. 2009. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149533.htm [Cited 22 August 2014]
   Google Scholar
• Sahyoun HA, Costall B, Naylor RJ. On the ability of domperidone to selectively inhibit catecholamine-induced relaxation of circular smooth muscle of guinea-pig stomach. J Pharm Pharmacol 1982;34(1):27-33
   PubMed Web of Science ®Google Scholar
• Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94(5):1230-4
   PubMed Web of Science ®Google Scholar
• Abrahamsson H. Treatment options for patients with severe gastroparesis. Gut 2007;56(6):877-83
   PubMed Web of Science ®Google Scholar
• Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011;56(1):115-24
   PubMed Web of Science ®Google Scholar
• Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98(2):259-63
   PubMed Web of Science ®Google Scholar
• Annese V, Lombardi G, Frusciante V, et al. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997;11(3):599-603
   PubMed Web of Science ®Google Scholar
• Jarvie EM, North Laidler VJ, Corcoran S, et al. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 2007;150(4):455-62
   PubMed Web of Science ®Google Scholar
• Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203-7
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56(1):1-18
   PubMed Web of Science ®Google Scholar
• Okudaira T, Kotegawa T, Imai H, et al. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007;47(7):871-6
   PubMed Web of Science ®Google Scholar
• Broad J, Mukherjee S, Samadi M, et al. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012;167(4):763-74
   PubMed Web of Science ®Google Scholar
• Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 2013;168:1859-67
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha A, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol 2011;9(1):1-16
   Google Scholar
• Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12(2):121-7
   PubMed Web of Science ®Google Scholar
• Mccallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e705-17
   PubMed Web of Science ®Google Scholar
• Sanger GJ. Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil 2014;26(2):149-55
   PubMed Web of Science ®Google Scholar
• Borrazzo EC. Surgical management of gastroparesis: gastrostomy/jejunostomy tubes, gastrectomy, pyloroplasty, gastric electrical stimulation. J Gastrointest Surg 2013;17(9):1559-61
   PubMed Web of Science ®Google Scholar
• O’Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg 2009;33(8):1693-701
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009;21(6):657-64. e30-1
   PubMed Web of Science ®Google Scholar
• Li JJ, Chao HG, Wang H, et al. Discovery of a Potent and Novel Motilin Agonist. J Med Chem 2004;47:1704-8
   PubMed Web of Science ®Google Scholar
• Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002;51(4):612; author reply 612-3
   PubMed Web of Science ®Google Scholar
• Deloose E, Vos R, Dewit O, et al. Evaluation of a new motilin receptor agonist, GSK962040, on the migrating motor complex and gastric ph in healthy human volunteers. Gastroenterology 2012;142(5):S-841
   Google Scholar
• Dukes GE, Barton M, Dewit O, et al. Safety/tolerability, pharmacokinetics (PK), and effect on gastric emptying(GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil 2010;22(S1):14-15
   Google Scholar
• Hellström PM, Tack JF, Stephens KE, et al. A double-blind, randomized placebo- controlled phase II study of the phar- macokinetics of single doses of the motilin agonist GSK962040, in patients with type I diabetes mellitus (TIDM) and gastroparesis. Gastroenterology 2011;140(S183):S-813
   Google Scholar
• Dukes G, Barton M, Dewit O, Hicks K. Pharmacokinetics, safety/tolerability, and effect on gastric emptying of the oral motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil 2009;21(Suppl 1):84
   Google Scholar
• Sanger GJ, Wang Y, Hobson A, Broad J. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol 2013;7):1323-32
   PubMed Web of Science ®Google Scholar
• Broad J, Góralczyk A, Mannur K, et al. Drugs acting at 5-HT4, D2, motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil 2014;26(6):851-61
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008;6:635-43
   PubMed Web of Science ®Google Scholar
• Vasist LS, Young MA, Stevens A, et al. A microtracer study of GSK962040, a motilin recepptor agonist, to support dosing regimens in the critical care setting. ASCPT Annual Meeting; Atlanta, GA; 2012
   Google Scholar
• Barton ME, Otiker T, Johnson LV, et al. A Randomized, double-blind, placebo-controlled Phase II study (MOT114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis. Gastroenterology 2014;146(5):S-20
   Google Scholar
• Barshop K, Semler JR, Barton ME, Dukes GE. An assessment of gastric and small bowel pressure profiles in diabetics with gastroparesis before and during 28 days of treatment with the motilin receptor agonist camicinal. ACG Annual Meeting; Philadelphia, PA; 2014
   Google Scholar
• Chapman M, Fraser R, Nguyen N, et al. The effect of GSK962040, a selective motilin agonist, on gastric emptying in critically ill patients with enteral feed intolerance. Crit Care Med 2011;39:195
   Google Scholar
• Javid F, Bulmer DC, Broad J, et al. Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. Eur J Pharmacol 2013;699(1-3):48-54
   PubMed Web of Science ®Google Scholar
• Vanderhoof JA, Young R, Kaufman SS, Ernst L. Treatment of cyclic vomiting in childhood with erythromycin. J Pediatr Gastroenterol Nutr 1993;17(4):387-91
   PubMed Web of Science ®Google Scholar
• Hobson A, Dewit O, O’Donnell MB, et al. Multimodal assessment of gastric residence time, whole bowel transit, esophageal function and gastro-esophageal reflux following administration of the motilin agonist (GSK962040) in healthy subjects. Gastroenterology 2012;142(5):S-842
   Google Scholar
• Zuo P, Vasist LS, Johnson LJ. Haberer. Improved success in candidate selection by early assessment of concentration-QTC relationship. ASCPT; Annual Meeting; Atlanta, GA; 2012
   Google Scholar
• Depoortere I. Can small non-peptide motilin agonists force a breakthrough as gastroprokinetic drugs? Br J Pharmacol 2012;167(4):760-2
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Alpers DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008;3):177-84
   PubMed Web of Science ®Google Scholar